...
首页> 外文期刊>British journal of ophthalmology >The association between statin use and age related maculopathy.
【24h】

The association between statin use and age related maculopathy.

机译:他汀类药物使用与年龄相关性黄斑病变之间的关联。

获取原文
获取原文并翻译 | 示例
           

摘要

AIMS: To evaluate the association between age related maculopathy (ARM) and statin use. METHODS: A nested case-control study among patients at the Veterans Affairs Medical Center in Birmingham, Alabama, with newly diagnosed ARM (cases) between 1997 to 2001 were selected and age matched to non-ARM controls. RESULTS: 550 incident cases of ARM were identified and matched to 5500 controls. Overall, cases were 70% (OR 0.30, 95% CI 0.21 to 0.45) less likely to have received and filled a statin prescription relative to the controls. This association was present among both current and past (OR 0.34, 95% CI 0.21 to 0.53 and OR 0.26, 95% CI 0.14 to 0.47, respectively) statin users. When considering use of statin and/or non-statin lipid lowering medications, a significant risk reduction was observed for statin only users (OR 0.30, 95% CI 0.20 to 0.45) and combined statin and non-statin users (OR 0.20, 95% CI 0.06 to 0.64); there was no significant association for non-statin only users (OR 0.47, 95% CI 0.20 to 1.13). CONCLUSIONS: The results of this study suggest that subjects with ARM were significantly less likely to have filled a statin prescription. Future clinical research initiatives should include a clinical trial to provide direct evidence of the effectiveness of statins in lowering the incidence and progression of ARM.
机译:目的:评估年龄相关性黄斑病(ARM)与他汀类药物使用之间的关联。方法:选择一项在阿拉巴马州伯明翰的退伍军人事务医疗中心的患者中进行的嵌套病例对照研究,研究对象为1997年至2001年之间新诊断的ARM(病例),并与非ARM对照年龄相匹配。结果:确定了550例ARM事件,并与5500例对照相匹配。总体而言,相对于对照组,接受和服用他汀类药物处方的可能性要低70%(OR 0.30,95%CI 0.21至0.45)。他汀类药物使用者目前和过去均存在这种关联(OR为0.34,95%CI为0.21至0.53,OR 0.26,95%CI为0.14至0.47)。当考虑使用他汀类和/或非他汀类降脂药物时,仅使用他汀类药物的使用者(OR 0.30,95%CI 0.20至0.45)以及使用他汀类和非他汀类药物的使用者(OR 0.20,95%)观察到显着降低风险CI 0.06至0.64);对于非他汀类药物使用者,则没有显着相关性(OR 0.47,95%CI 0.20至1.13)。结论:这项研究的结果表明,患有ARM的受试者服用他汀类药物的可能性大大降低。未来的临床研究计划应包括一项临床试验,以提供他汀类药物在降低ARM发生率和进展中的有效性的直接证据。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号